Cubist Pharms Drug Patent Portfolio
Cubist Pharms owns 1 orange book drug protected by 6 US patents Given below is the list of Cubist Pharms's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8112290 | Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug | 31 Jul, 2030 | Active |
US8946262 | Methods of preventing and treating gastrointestinal dysfunction | 12 Feb, 2030 | Active |
US8645160 | Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug | 18 Jun, 2029 | Active |
US6469030 | Methods for the treatment and prevention of ileus | 29 Nov, 2020 | Expired |
US5250542 | Peripherally selective piperidine carboxylate opioid antagonists | 29 Mar, 2016 | Expired |
US5434171 | Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates | 08 Dec, 2013 | Expired |
Latest Legal Activities on Cubist Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Cubist Pharms.
Activity | Date | Patent Number |
---|---|---|
Payment of Maintenance Fee, 12th Year, Large Entity | 13 Jul, 2023 | US8112290 |
Payment of Maintenance Fee, 8th Year, Large Entity | 16 Jul, 2019 | US8112290 |
Change in Power of Attorney (May Include Associate POA)
Critical
| 13 Jul, 2016 | US8112290 |
Email Notification
Critical
| 13 Jul, 2016 | US8112290 |
Correspondence Address Change
Critical
| 12 Jul, 2016 | US8112290 |
Email Notification
Critical
| 12 Apr, 2012 | US8112290 |
Change in Power of Attorney (May Include Associate POA)
Critical
| 12 Apr, 2012 | US8112290 |
Correspondence Address Change
Critical
| 06 Apr, 2012 | US8112290 |
Recordation of Patent Grant Mailed
Critical
| 07 Feb, 2012 | US8112290 |
Patent Issue Date Used in PTA Calculation
Critical
| 07 Feb, 2012 | US8112290 |
Issue Notification Mailed
Critical
| 18 Jan, 2012 | US8112290 |
Dispatch to FDC | 04 Jan, 2012 | US8112290 |
Application Is Considered Ready for Issue
Critical
| 04 Jan, 2012 | US8112290 |
Issue Fee Payment Received
Critical
| 29 Dec, 2011 | US8112290 |
Issue Fee Payment Verified
Critical
| 29 Dec, 2011 | US8112290 |
Cubist Pharms's Family Patents
Cubist Pharms drugs have patent protection in a total of 1 countries. It has a significant patent presence in the US with 100.0% of its patents being US patents. Click
below to unlock the full patent family tree.
Cubist Pharms Drug List
Given below is the complete list of Cubist Pharms's drugs and the patents protecting them.
1. Entereg
Entereg is protected by 6 patents, out of which 3 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8112290 | Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug |
31 Jul, 2030
(5 years from now)
| Active |
US8946262 | Methods of preventing and treating gastrointestinal dysfunction |
12 Feb, 2030
(5 years from now)
| Active |
US8645160 | Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug |
18 Jun, 2029
(4 years from now)
| Active |
US6469030 | Methods for the treatment and prevention of ileus |
29 Nov, 2020
(3 years ago)
| Expired |
US5250542 | Peripherally selective piperidine carboxylate opioid antagonists |
29 Mar, 2016
(8 years ago)
| Expired |
US5434171 | Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates |
08 Dec, 2013
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Entereg's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List